Exec Chat: John Frels, VP Of Research And Development, Abbott Diagnostics
Medtech Insight caught up with Abbott's John Frels to find out more on his approach to leading innovation and growth at the company.
You may also be interested in...
A landmark trial of Abbott Laboratories' point-of-care blood test for traumatic brain injuries shows the test could identify patients who should undergo magnetic resonance imaging (MRI), even after a computed tomography (CT) scan did not show a brain injury.
Abbott delivered solid sales growth in the second quarter of 2019, topping analyst expectations. The company reported worldwide sales of $8bn, up 2.7% with Medical Devices highlighted as a standout division, delivering 10.5% organic growth.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.